Piperazinyl-glutamate-pyrimidines were prepared with oxygen, nitrogen, and sulfur substitution at the 4-position of the pyrimidine leading to highly potent P2Y12 antagonists. In particular, 4-substituted piperidine-4-pyrimidines provided compounds with exceptional potency. Pharmacokinetic and physicochemical properties were fine-tuned through modifications at the 4-position of the piperidine ring leading to compounds with good human PRP potency, selectivity, clearance and oral bioavailability.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2009.09.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
STEMI Antithrombotic Therapy: The Evolving Role of P2Y12 Inhibitor Pretreatment in Contemporary Practice.
Rev Cardiovasc Med
November 2024
Cardiology Unit, Sant'Andrea University Hospital, 00189 Rome, Italy.
Article Synopsis
- The P2Y12 receptor is crucial for platelet activation and has been a focus of research, particularly in the context of treating acute coronary syndromes (ACS) with dual therapy of aspirin and clopidogrel, as shown in the landmark CURE trial from 2001.
- Advances in interventional cardiology, including drug-eluting stents and new P2Y12 inhibitors like ticagrelor and prasugrel, have significantly changed ACS treatment but challenges still exist, particularly with ST-elevation myocardial infarction (STEMI).
- The review highlights the efficacy and safety of using P2Y12 receptor antagonists as a pretreatment strategy for STEMI, stressing the need for personalized treatment plans and the future
The Comparative Effectiveness of Potent P2Y12 Inhibitors Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing PCI: National Registry Data.
J Clin Med
October 2024
Heart Institute, Medical School, University of Pécs, 7622 Pécs, Hungary.
Dual antiplatelet therapy (DAPT), which is essential in AMI management, combines aspirin with a P2Y12 receptor antagonist. This study compared the effectiveness of potent P2Y12 inhibitors versus clopidogrel in AMI patients treated with percutaneous coronary intervention (PCI). 65,986 AMI patients included in a nationwide prospective registry who underwent PCI and received DAPT were studied.
View Article and Find Full Text PDFBreaking boundaries: Ticagrelor monotherapy in high-risk patients.
Int J Cardiol Heart Vasc
December 2024
Medical Affairs, AstraZeneca Pharma India Ltd, India.
Atherosclerotic plaque formation is a leading cause of arterial thrombosis that significantly impacts global health by instigating major adverse cardiovascular events (MACE) like myocardial infarction (MI) and stroke. Platelets are central to this process, leading to the development of antiplatelet therapies, to mitigate MACE risks. The combination of aspirin with a potent P2Y inhibitor known as dual antiplatelet therapy (DAPT) is the standard for post-percutaneous coronary intervention (PCI) aimed at reducing ischemic events.
View Article and Find Full Text PDFSwitching from cangrelor to oral P2Y inhibitors: a focused review on drug-drug interactions.
Expert Opin Drug Metab Toxicol
January 2025
Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.
Article Synopsis
- Cangrelor is an intravenous medication that inhibits platelet P2Y receptors, effectively preventing blood clots during procedures like coronary interventions, especially in patients not on oral P2Y inhibitors.
- Its rapid platelet inhibition raises concerns about potential drug-drug interactions (DDIs) when switching to oral P2Y inhibitors, which is critical for patient safety.
- Proper timing during the transition to oral P2Y inhibitors, particularly clopidogrel and prasugrel, is crucial to minimize DDI risks, and following existing guidelines can enhance treatment outcomes.
Role of ticagrelor in the peri-thrombolytic phase for patients with ST-segment elevation myocardial infarction: a comprehensive review.
Thromb J
October 2024
Department of Cardiology, West China Hospital of Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China.
Article Synopsis
- Ticagrelor is a new and effective P2Y12 inhibitor used in managing patients with STEMI, showing advantages over the traditional drug clopidogrel in preventing blood clots after treatment.
- *Key clinical trials, including TREAT and MIRTOS, demonstrate ticagrelor's superior ability to inhibit platelets without significantly increasing bleeding risks, suggesting it's a promising option.
- *Despite its potential benefits, clopidogrel is still the recommended treatment, so more research is needed to better understand ticagrelor's long-term impacts and best usage in cardiovascular care.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!